Logo image of EPIX

ESSA PHARMA INC (EPIX) Stock Fundamental Analysis

NASDAQ:EPIX - Nasdaq - CA29668H7085 - Common Stock - Currency: USD

1.68  -0.02 (-1.18%)

Fundamental Rating

3

EPIX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 557 industry peers in the Biotechnology industry. EPIX has a great financial health rating, but its profitability evaluates not so good. EPIX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year EPIX has reported negative net income.
In the past year EPIX has reported a negative cash flow from operations.
EPIX had negative earnings in each of the past 5 years.
In the past 5 years EPIX always reported negative operating cash flow.
EPIX Yearly Net Income VS EBIT VS OCF VS FCFEPIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

EPIX has a Return On Assets of -24.69%. This is in the better half of the industry: EPIX outperforms 73.61% of its industry peers.
With an excellent Return On Equity value of -25.10%, EPIX belongs to the best of the industry, outperforming 81.51% of the companies in the same industry.
Industry RankSector Rank
ROA -24.69%
ROE -25.1%
ROIC N/A
ROA(3y)-20.28%
ROA(5y)-21.7%
ROE(3y)-20.7%
ROE(5y)-22.14%
ROIC(3y)N/A
ROIC(5y)N/A
EPIX Yearly ROA, ROE, ROICEPIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for EPIX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EPIX Yearly Profit, Operating, Gross MarginsEPIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

9

2. Health

2.1 Basic Checks

EPIX has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, EPIX has more shares outstanding
EPIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
EPIX Yearly Shares OutstandingEPIX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
EPIX Yearly Total Debt VS Total AssetsEPIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

EPIX has an Altman-Z score of 21.75. This indicates that EPIX is financially healthy and has little risk of bankruptcy at the moment.
EPIX has a better Altman-Z score (21.75) than 94.25% of its industry peers.
There is no outstanding debt for EPIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 21.75
ROIC/WACCN/A
WACCN/A
EPIX Yearly LT Debt VS Equity VS FCFEPIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

EPIX has a Current Ratio of 67.17. This indicates that EPIX is financially healthy and has no problem in meeting its short term obligations.
EPIX has a Current ratio of 67.17. This is amongst the best in the industry. EPIX outperforms 99.64% of its industry peers.
EPIX has a Quick Ratio of 67.17. This indicates that EPIX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 67.17, EPIX belongs to the top of the industry, outperforming 99.64% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 67.17
Quick Ratio 67.17
EPIX Yearly Current Assets VS Current LiabilitesEPIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for EPIX have decreased by 0.00% in the last year.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 72.82% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-13.16%
EPS Next 2Y21.08%
EPS Next 3Y6.83%
EPS Next 5Y72.82%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPIX Yearly Revenue VS EstimatesEPIX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2029 2030 2031 2032 200M 400M 600M 800M
EPIX Yearly EPS VS EstimatesEPIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EPIX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EPIX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EPIX Price Earnings VS Forward Price EarningsEPIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EPIX Per share dataEPIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.08%
EPS Next 3Y6.83%

More info and screens

0

5. Dividend

5.1 Amount

EPIX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ESSA PHARMA INC

NASDAQ:EPIX (6/17/2025, 10:15:01 AM)

1.68

-0.02 (-1.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-04 2025-08-04/bmo
Inst Owners69.42%
Inst Owner Change-2.9%
Ins Owners2.24%
Ins Owner Change0%
Market Cap74.58M
Analysts45.71
Price Target1.73 (2.98%)
Short Float %1.64%
Short Ratio4.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.14%
Min EPS beat(2)-3.49%
Max EPS beat(2)27.76%
EPS beat(4)3
Avg EPS beat(4)22.53%
Min EPS beat(4)-3.49%
Max EPS beat(4)36.23%
EPS beat(8)6
Avg EPS beat(8)20.6%
EPS beat(12)10
Avg EPS beat(12)25.26%
EPS beat(16)14
Avg EPS beat(16)22.11%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-8.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-100%
EPS NY rev (1m)0%
EPS NY rev (3m)-47.15%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.66
P/tB 0.66
EV/EBITDA N/A
EPS(TTM)-0.63
EYN/A
EPS(NY)-0.34
Fwd EYN/A
FCF(TTM)-0.51
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS0
BVpS2.56
TBVpS2.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.69%
ROE -25.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-20.28%
ROA(5y)-21.7%
ROE(3y)-20.7%
ROE(5y)-22.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 67.17
Quick Ratio 67.17
Altman-Z 21.75
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
EPS Next Y-13.16%
EPS Next 2Y21.08%
EPS Next 3Y6.83%
EPS Next 5Y72.82%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y2.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.26%
OCF growth 3YN/A
OCF growth 5YN/A